株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

消化管間質腫瘍 (GIST) :世界の治験動向

Gastrointestinal Stromal Tumor (GIST) Global Clinical Trials Review, H2, 2017

発行 GlobalData 商品コード 229136
出版日 ページ情報 英文 323 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.40円で換算しております。
Back to Top
消化管間質腫瘍 (GIST) :世界の治験動向 Gastrointestinal Stromal Tumor (GIST) Global Clinical Trials Review, H2, 2017
出版日: 2017年08月23日 ページ情報: 英文 323 Pages
概要

当レポートでは、世界における消化管間質腫瘍 (GIST) 治療薬の治験について調査しており、地域別、段階別、進捗状況別の治験動向、治験に携わっている主な企業や有望な薬剤の情報、最新の治験関連ニュースなどを提供しています。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要5カ国における治験件数
    • 中南米の主要5カ国における治験件数

G7諸国での治験件数:癌治療薬の治験における消化管間質腫瘍 (GIST) の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:癌治療薬の治験における消化管間質腫瘍 (GIST) の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

消化管間質腫瘍 (GIST) 治療薬の治験に携わっている主要企業

有望な薬剤

最新の治験ニュース

治験プロファイルの概要

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC4500CTIDB

GlobalData's clinical trial report, "Gastrointestinal Stromal Tumor (GIST) Global Clinical Trials Review, H2, 2017" provides an overview of Gastrointestinal Stromal Tumor (GIST) clinical trials scenario. This report provides top line data relating to the clinical trials on Gastrointestinal Stromal Tumor (GIST). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
  • Top Five Countries Contributing to Clinical Trials in Europe 13
  • Top Countries Contributing to Clinical Trials in North America 14
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
  • Top Five Countries Contributing to Clinical Trials in Central and South America 16
  • Clinical Trials by G7 Countries: Proportion of Gastrointestinal Stromal Tumor (GIST) to Oncology Clinical Trials 17
  • Clinical Trials by Phase in G7 Countries 18
  • Clinical Trials in G7 Countries by Trial Status 19
  • Clinical Trials by E7 Countries: Proportion of Gastrointestinal Stromal Tumor (GIST) to Oncology Clinical Trials 20
  • Clinical Trials by Phase in E7 Countries 21
  • Clinical Trials in E7 Countries by Trial Status 22
  • Clinical Trials by Phase 23
  • In Progress Trials by Phase 24
  • Clinical Trials by Trial Status 25
  • Clinical Trials by End Point Status 26
  • Subjects Recruited Over a Period of Time 27
  • Clinical Trials by Sponsor Type 28
  • Prominent Sponsors 29
  • Top Companies Participating in Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials 31
  • Prominent Drugs 33
  • Latest Clinical Trials News on Gastrointestinal Stromal Tumor (GIST) 34
  • Aug 19, 2017: Patients with advanced cancer survive 10 years on first targeted cancer wonder drug 34
  • Aug 17, 2017: Immunicum Completes Strategic Analysis and Defines Updated Clinical Development Plan for Ilixadencel 34
  • Aug 02, 2017: Blueprint Medicines Provides Update on Clinical Program of its Cancer Drug, BLU-285 35
  • Jun 05, 2017: Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFRa D842V Mutation 35
  • Jun 05, 2017: Deciphera Pharmaceuticals Reports Updated Phase 1 Clinical Study Results with DCC-2618 at 2017 American Society of Clinical Oncology Annual Meeting 37
  • Clinical Trial Profile Snapshots 38

Appendix 320

  • Abbreviations 320
  • Definitions 320
  • Research Methodology 321
  • Secondary Research 321
  • About GlobalData 322
  • Contact Us 322
  • Disclaimer 323
  • Source 323

List of Tables

List of Tables

  • Gastrointestinal Stromal Tumor (GIST) Therapeutics, Global, Clinical Trials by Region, 2017* 8
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 15
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16
  • Proportion of Gastrointestinal Stromal Tumor (GIST) to Oncology Clinical Trials, G7 Countries (%), 2017* 17
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
  • Proportion of Gastrointestinal Stromal Tumor (GIST) to Oncology Clinical Trials, E7 Countries (%), 2017* 20
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 22
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics, Global, Clinical Trials by Phase, 2017* 23
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 24
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 25
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 26
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 27
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 28
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 30
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 32
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 33

List of Figures

List of Figures

  • Gastrointestinal Stromal Tumor (GIST) Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 15
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16
  • Proportion of Gastrointestinal Stromal Tumor (GIST) to Oncology Clinical Trials, G7 Countries (%), 2017* 17
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
  • Proportion of Gastrointestinal Stromal Tumor (GIST) to Oncology Clinical Trials, E7 Countries (%), 2017* 20
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 22
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 23
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 24
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 25
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 26
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 27
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 28
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31
  • Gastrointestinal Stromal Tumor (GIST) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 33
  • GlobalData Methodology 321
Back to Top